Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Gulley Website

James L. Gulley, M.D., Ph.D.

Selected Publications

1)  Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Cancer Immunol. Immunother. 63: 407-18, 2014.
[Journal]
2)  Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Int. J. Cancer. 2014.
[Journal]
3)  Singh BH, Gulley JL.
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
Asian J. Androl. 2014.
[Journal]
4)  O'Sullivan Coyne G, Madan RA, Gulley JL.
Nivolumab: promising survival signal coupled with limited toxicity raises expectations.
J. Clin. Oncol. 32: 986-8, 2014.
[Journal]
5)  Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B.
Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy.
J. Immunol. 192: 2622-33, 2014.
[Journal]
6)  Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F.
Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
Oncoimmunology. 2: e27025, 2013.
[Journal]
7)  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol. Immunother. [Epub ahead of print], 2013.
[Journal]
8)  Madan RA, Gulley JL.
Prostate cancer: Intermediate efficacy end points to assess modern therapies.
Nat Rev Urol. 10: 686-7, 2013.
[Journal]
9)  Madan RA, Gulley JL, Kantoff PW.
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
Cancer J. 19: 50-8, 2013.
[Journal]
10)  Rojan A, Funches R, Regan MM, Gulley JL, Bubley GJ.
Dramatic and prolonged PSA response after retreatment with a PSA vaccine.
Clin Genitourin Cancer. 11: 362-4, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/2/2014.